The Michigan Department of Health and Human Services added FDA approved biosimilar alternatives to Stelara (ustekinumab) to the Medicaid Preferred Drug List. Stelara, is listed as non-preferred, and the biosimilars Pyzchiva and Steqeyma are currently listed as preferred. 

The following ustekinumab products are now included on the PDL: 

• Pyzchiva (ustekinumab-kfce)
• Steqeyma (ustekinumab-stba)
• Stelara (ustekinumab)

The addition of these biosimilar products provides prescribers with expanded treatment options for patients who may benefit from targeted biologic therapy. Providers should continue to follow standard prior authorization requirements and consult the most recent Michigan PDL for coverage details. 

Click here to read the full Provider Notice.